ALNY Stock Risk & Deep Value Analysis

Alnylam Pharmaceuticals, Inc.

DVR Score

8.1

out of 10

Hidden Gem

The Bottom Line on ALNY

We analyzed Alnylam Pharmaceuticals, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran ALNY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 6, 2025•Run Fresh Analysis →

📈ALNY Performance Overview3yr weekly

📊

Unlock ALNY Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

ALNY Deep Value Analysis

Alnylam exhibits a strong, validated RNAi platform with a significant IP moat, multiple approved products, and a clear path to profitability. Positive Phase 3 data for Zilebesiran in hypertension presents a massive TAM expansion catalyst, driving potential for multi-bagger returns. Excellent leadership, strong financials, and robust institutional backing underpin this. However, achieving 10x from its current ~$20B market cap necessitates flawless commercial execution for Zilebesiran in a highly competitive market, and consistent, high-impact pipeline successes beyond, which represents significant execution risk despite the strong foundation.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

🔔

Never miss a move on ALNY

Create a free account to set price alerts and get notified on Telegram when ALNY hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Alnylam Pharmaceuticals, Inc. (ALNY)?

As of September 6, 2025, Alnylam Pharmaceuticals, Inc. has a DVR Score of 8.1 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

How often is the ALNY DVR analysis updated?

Our AI-powered analysis of Alnylam Pharmaceuticals, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on September 6, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.